File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Relationship between hepatocellular carcinoma development and serum viral markers in chronic hepatitis B patients who achieved undetectable serum HBV DNA while on long-term nucleoside analogue therapy

TitleRelationship between hepatocellular carcinoma development and serum viral markers in chronic hepatitis B patients who achieved undetectable serum HBV DNA while on long-term nucleoside analogue therapy
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2015
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD Liver Meeting 2015), San Francisco, CA., 13-17 November 2015. In Hepatology, 2015, v. 62 suppl. S1, p. 273A, abstract no. 126 How to Cite?
AbstractBACKGROUND: Hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) are risk factors for the development of hepatocellular carcinoma (HCC). Linearized HBsAg (HQ-HBsAg) is a more sensitive assay to measure HBsAg level. However, their roles in predicting HCC development are unknown when there is profound viral suppression by nucleos(t)ide analogues (NA). METHODS: Seventy-six chronic hepatitis B (CHB) patients who developed HCC in 2007-2014 despite undetectable serum HBV DNA level after at least one-year NA therapy were recruited. 152 CHB patients without HCC were recruited as controls. They were matched by age, gender, HBeAg status, cirrhosis status, undetectable serum HBV DNA and duration of NA therapy with the 76 HCC patients in a 2:1 ratio. Serum HBsAg, HQ-HBsAg and HBcrAg levels were analysed and compared between the two groups. RESULTS: A statistically significant difference in the HBcrAg level was noted between the HCC group and non-HCC groups (10.2 and 1.7 kU/mL respectively, p=0.005), but was not observed in HBsAg or HQ-HBsAg levels. The area under receiver operating characteristic curve (AUROC) was 0.61 (95% CI: 0.54-0.69) with a negative predictive value (NPV) of 77.0% when a cutoff value of HBcrAg level ≥7.8 kU/mL was used. The odds ratio of HCC development was 3.27 (95% CI: 1.84-5.80). In the subgroup analysis for non-cirrhotic patients, a statistically significant difference in the HBcrAg level was noted between the HCC group and non-HCC groups (10.2 and 1.0 kU/mL respectively, p=0.001). The AUROC was 0.70 (95% CI: 0.58-0.81) with a NPV of 80.6% when a cutoff value of HBcrAg level ≥7.9 kU/mL was used. The odds ratio of HCC development was 5.95 (95% CI: 2.35-15.07). CONCLUSION: HBcrAg (but not HBsAg or HQ-HBsAg) can predict HCC risk in CHB patients who achieve undetectable serum HBV DNA while receiving NA therapy. Future prospective studies are warranted to further define the role of HBcrAg level in this group of patients.
DescriptionOral Presentation - Parallel 18: Hepatobiliary Neoplasia 1: no. 126
This FREE journal suppl. entitled: Special Issue: The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015
Persistent Identifierhttp://hdl.handle.net/10722/226489
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorCheung, KS-
dc.contributor.authorSeto, WK-
dc.contributor.authorWong, D-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, MF-
dc.date.accessioned2016-06-17T07:44:28Z-
dc.date.available2016-06-17T07:44:28Z-
dc.date.issued2015-
dc.identifier.citationThe 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD Liver Meeting 2015), San Francisco, CA., 13-17 November 2015. In Hepatology, 2015, v. 62 suppl. S1, p. 273A, abstract no. 126-
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/226489-
dc.descriptionOral Presentation - Parallel 18: Hepatobiliary Neoplasia 1: no. 126-
dc.descriptionThis FREE journal suppl. entitled: Special Issue: The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015-
dc.description.abstractBACKGROUND: Hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) are risk factors for the development of hepatocellular carcinoma (HCC). Linearized HBsAg (HQ-HBsAg) is a more sensitive assay to measure HBsAg level. However, their roles in predicting HCC development are unknown when there is profound viral suppression by nucleos(t)ide analogues (NA). METHODS: Seventy-six chronic hepatitis B (CHB) patients who developed HCC in 2007-2014 despite undetectable serum HBV DNA level after at least one-year NA therapy were recruited. 152 CHB patients without HCC were recruited as controls. They were matched by age, gender, HBeAg status, cirrhosis status, undetectable serum HBV DNA and duration of NA therapy with the 76 HCC patients in a 2:1 ratio. Serum HBsAg, HQ-HBsAg and HBcrAg levels were analysed and compared between the two groups. RESULTS: A statistically significant difference in the HBcrAg level was noted between the HCC group and non-HCC groups (10.2 and 1.7 kU/mL respectively, p=0.005), but was not observed in HBsAg or HQ-HBsAg levels. The area under receiver operating characteristic curve (AUROC) was 0.61 (95% CI: 0.54-0.69) with a negative predictive value (NPV) of 77.0% when a cutoff value of HBcrAg level ≥7.8 kU/mL was used. The odds ratio of HCC development was 3.27 (95% CI: 1.84-5.80). In the subgroup analysis for non-cirrhotic patients, a statistically significant difference in the HBcrAg level was noted between the HCC group and non-HCC groups (10.2 and 1.0 kU/mL respectively, p=0.001). The AUROC was 0.70 (95% CI: 0.58-0.81) with a NPV of 80.6% when a cutoff value of HBcrAg level ≥7.9 kU/mL was used. The odds ratio of HCC development was 5.95 (95% CI: 2.35-15.07). CONCLUSION: HBcrAg (but not HBsAg or HQ-HBsAg) can predict HCC risk in CHB patients who achieve undetectable serum HBV DNA while receiving NA therapy. Future prospective studies are warranted to further define the role of HBcrAg level in this group of patients.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatology-
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.rightsPreprint: This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Postprint: This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Special Statement for Preprint only Before publication: 'This is a preprint of an article accepted for publication in [The Journal of Pathology] Copyright © ([year]) ([Pathological Society of Great Britain and Ireland])'. After publication: the preprint notice should be amended to follows: 'This is a preprint of an article published in [include the complete citation information for the final version of the Contribution as published in the print edition of the Journal]' For Cochrane Library/ Cochrane Database of Systematic Reviews, add statement & acknowledgement : ‘This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 20XX, Issue X. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.’ Please include reference to the Review and hyperlink to the original version using the following format e.g. Authors. Title of Review. Cochrane Database of Systematic Reviews 20XX, Issue #. Art. No.: CD00XXXX. DOI: 10.1002/14651858.CD00XXXX (insert persistent link to the article by using the URL: http://dx.doi.org/10.1002/14651858.CD00XXXX) (This statement should refer to the most recent issue of the Cochrane Database of Systematic Reviews in which the Review published.)-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleRelationship between hepatocellular carcinoma development and serum viral markers in chronic hepatitis B patients who achieved undetectable serum HBV DNA while on long-term nucleoside analogue therapy-
dc.typeConference_Paper-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailWong, D: danywong@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityWong, D=rp00492-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi0.1002/hep.28187-
dc.identifier.hkuros258652-
dc.identifier.volume62-
dc.identifier.issuesuppl. S1-
dc.identifier.spage273A, abstract no. 126-
dc.identifier.epage273A, abstract no. 126-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats